Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 44-51

  Seiter, K ^a   Feldman, E J ^a   Halicka, H D ^a   Traganos, F ^a   Darzynkiewicz, Z ^a   Lake, D ^a   Ahmed, T ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; TOPOTECAN;

ACUTE LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD CELL COUNT; CELL CYCLE S PHASE; CLINICAL TRIAL; DNA STRAND BREAKAGE; DOSE CALCULATION; FEMALE; FLOW CYTOMETRY; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031027077     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.44     Document Type: Article

References (23)

1. Liu LF: DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 58:351-375, 1989
2. Rowinsky EK, Grochow LB, Hendricks CB, et al: Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992
3. Wall JG, Burris HA, von Hoff DD, et al: A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 3:337-346, 1992
4. Saltz L, Sirott M, Young C, et al: Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 85:1499-1507, 1993
5. Burris HA, Awada A, Kuhn JG, et al: Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 hour continuous infusion. Anticancer Drugs 5:394-402, 1994
6. Kantarjian HM, Beran M, Ellis A, et al: Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81:1146-1151, 1993
7. Rowinsky EK, Adjei A, Donehower RC, et al: Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 12:2193-2203, 1994
8. Darzynkiewicz Z, Bruno S, Del Bino G, et al: The cell cycle effects of camptothecin. Ann NY Acad Sci (in press)
9. Kano Y, Suzuki K, Akutsu M, et al: Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50:604-610, 1992
10. Kaufmann SH: Induction of endonucleocytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other anticancer drugs: A cautionary note. Cancer Res 49:5870-5878, 1989
11. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metast Rev 11:121-139, 1992
12. Solary E, Bertrand R, Kohn KW, et al: Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase inhibitors. Blood 81:1353-1368, 1993
13. Li X, Gong J, Feldman E, et al: Apoptotic cell death during treatment of leukemias. Leuk Lymphoma 13:65-70, 1994 (suppl)
14. Seiter K, Feldman EJ, Traganos F, et al: Evaluation of in vivo induction of apoptosis in patients with acute leukemia treated on a phase I study of paclitaxel. Leukemia 9:1961-1983, 1995
15. Traganos F, Seiter K, Feldman E, et al: Induction of apoptosis by camptothecin and topotecan. Ann NY Acad Sci 803:1-10, 1996
16. Darzynkiewiez Z, Bruno S, Del Bino G, et al: Features of apoptotic cells measured by flow cytometry. Cytometry 13:795-808, 1992
17. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the acute leukaemias. Br J Hematol 33:451-458, 1976
18. Guidelines for the Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
19. Gorczyca W, Gong J, Darzynkiewicz Z: Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res 53:1945-1951, 1993
20. Hendricks CB, Rowinsky EK, Grochow LB, et al: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52:2268-2278, 1992
21. Marie JP, Legrand O, Russo D, et al: Multidrug resistance (MDR) gene expression in acute non lymphoblastic leukemia: Sequential analysis. Leuk Lymphoma 8:261-265, 1992
22. Feldman E, Traganos F, Seiter K, et al: High dose mitoxantrone induces apoptosis-associated DNA strand breaks in patients with acute myelogenous leukemia. Blood 82:124a, 1993 (suppl 1, abstr)
23. Darzynkiewicz Z, Li X, Gong J, et al: Analysis of cell death by flow cytometry, in Studzinski GP (ed): Cell Growth and Apoptosis. New York, NY, IRL, 1995, pp 143-167